Johns Hopkins IRB Approves Advancement of CMND-100 Clinical Trial to Next Stages
CMND sits 17% above its 52-week low of $2.1 on light trading volume (0.2× avg).
Summary
Clearmind Medicine received approval from Johns Hopkins IRB to advance its CMND-100 Phase I/II clinical trial for Alcohol Use Disorder to Parts B and C, marking a significant step in its drug development.
Key Events · Product Development and Regulatory · CMND
-
IRB Approval for CMND-100 Trial Advancement
The Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for Clearmind Medicine to advance its ongoing Phase I/II clinical trial of CMND-100.
-
Progression to Parts B and C
This approval permits the company to proceed with Parts B and C of the multi-center study, which is evaluating CMND-100 in healthy volunteers and Alcohol Use Disorder (AUD) subjects.
-
Significant Clinical Development Milestone
This milestone follows the successful completion of earlier trial stages and represents an important step forward in the clinical development program for CMND-100, a non-hallucinogenic MEAI-based candidate for AUD.
Analysis · CMND · Life Sciences
This approval from Johns Hopkins IRB to advance the CMND-100 Phase I/II clinical trial to Parts B and C is a significant de-risking event for Clearmind Medicine. For a clinical-stage biotech company, successful progression through trial phases is critical, validating the drug candidate's safety and tolerability and moving it closer to potential commercialization. This positive clinical development follows a recent 1-for-10 reverse stock split on May 21, 2026, and a series of convertible note issuances, suggesting the company is actively working to strengthen its position and advance its pipeline.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $2.10 to $524.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.